Location: Foreign Animal Disease Research
Project Number: 8064-32000-061-56-S
Project Type: Non-Assistance Cooperative Agreement
Start Date: Mar 1, 2019
End Date: Aug 31, 2020
Foot-and-mouth disease virus (FMDV) is the most devastating disease affecting livestock worldwide. Vaccines to protect against FMD are needed to protect U.S. agriculture from accidental or intentional introduction of FMDV from regions where the virus is endemic. Like other RNA viruses FMDV is antigenically diverse, and effective vaccination currently requires matching between vaccines and target viral isolates based on serology or sequence-based prediction. The objective of this research project is to support the development of novel FMDV vaccine candidates and the examination of animal immune responses in the natural host. It will also contribute to generate knowledge on next generation FMDV vaccines, virus characterization and serological responses in animals, that will ultimately help to prevent and control FMD. The goal of this collaborative research project is to provide molecular and immunological support to USDA, ARS in the characterization, evaluation and data analysis of novel FMDV vaccine candidates. Specific objectives include: 1. Formulate mosaic type A FMDV vaccine and evaluate protective efficacy and their immunogenic coverage compared to monovalent type A vaccine in cattle using heterologous challenge. 2. Evaluate serological responses in animal: protective antibody and T-lymphocyte responses in cattle or swine immunized with parental or with Mosaic vaccine. 3. Continue to build technical capacity to individuals that could expand their expertise on foreign animal diseases, and potentcially transition to the National Bio-and Agro Defense Facility (NBAF) in the near future.
The Kansas State University (KSU) will provide the USDA, ARS support in the characterization and in vivo evaluation of novel FMDV vaccine candidates. Activities will include: 1. The development of recombinant type A mosaic 2.1/2.2 mosaic and A24Cru vaccines and evaluation of their ability to protect against clinical disease in cattle challenged with heterologous FMDV strain, following according to the OIE manual. 2. Develop and conduct animal experiment designs to test vaccine efficacy which will include collection of appropriate samples to assess if novel vaccines prevent clinical FMD against heterologous chalenge. Determine the cellular immune response, specifically induction of cytotoxic T lymphocytes (CTL) that can kill virus-infected cells in a FMDV specific manner.